Business
CHAMPIONS ONCOLOGY, INC.: our business strategies and products development activities, including the anticipated benefits and risks associated with those strategies as well as statements about the sufficiency of our capital resources.
Revenue increased 13.5% to $56.9M, while Net income increased 164.6% to $4.7M.
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $56.9MOK
- Profitability — Net income $4.7MOK
- Cash generation — Free cash flow $7.0MOK
- Accounting — Formula distress score · no manipulation flag · earnings quality safeWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — share repurchases were $0Note
Where the revenue comes from
Fiscal 2026, as CHAMPIONS ONCOLOGY, INC. reports it. History and quarterly detail are in the app.
- Pharmacology services$57.1M
- Other TOS revenue$1.5M
- TOS data license revenue$764K
Leadership changes
From CHAMPIONS ONCOLOGY, INC.'s own filings, the day they're filed.
- Philip Breitfeld · director · departureeff. 2026-03-24
- Brady Davis · President · departure
Latest filings
- 8-K · Company announcement2026-07-27
- 10-K · Annual report2026-07-27
- 8-K · Company announcement2026-03-30
- 10-Q · Quarterly report2026-03-12
- 8-K · Company announcement2026-03-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CHAMPIONS ONCOLOGY, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.